Contact
Contact Us
Exo Therapeutics, Inc.
150 Cambridge Park Dr
Suite 300
Cambridge, MA 02140
Email: [email protected]
Exo has assembled a team of seasoned industry leaders, world class investors and expert advisors.
Exo Therapeutics, Inc.
150 Cambridge Park Dr
Suite 300
Cambridge, MA 02140
Email: [email protected]
Alan Saghatelian, PhD
Co-Founder
Alan Saghatelian, PhD, is a Professor and Frederik Paulsen Chair at the Salk Institute for Biological Studies and an adjunct Professor at the University of California, San Diego.
Dr. Saghatelian has published over 110 papers and six patents. Saghatelian was a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation Fellow. Dr. Saghatelian’s research in chemical biology merges modern analytical techniques with biochemistry and chemical biology to identify genes that regulate fundamental biological pathways and can be targeted for the development of novel therapeutics.
Dr. Saghatelian graduated from the University of California, Los Angeles in 1997 with a degree in Chemistry. He carried out organic and organometallic chemistry research on the total synthesis of a marine natural product with anti-cancer activity in the lab of Professor Craig Merlic. He earned his PhD in Chemistry from The Scripps Research Institute in Chemistry working with Professor Reza Ghadiri. During graduate school, Dr. Saghatelian worked to develop new protein and peptide catalysts through chemical synthesis and protein engineering. Dr. Saghatelian performed his postdoctoral research with Professor Benjamin Cravatt at The Scripps Research Institute where he developed novel mass spectrometry approaches for global metabolite profiling. In 2006, Dr. Saghatelian started his independent career as an Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University, and in 2014, he moved to the Salk Institute for Biological Studies.
Ronenn Roubenoff, MD
Senior Clinical Advisor
Ronenn Roubenoff, MD, brings decades of experience in clinical and translational medicine; including expertise across auto-immune and metabolic diseases and pioneering work in biomarkers. Prior to Exo, Dr. Roubenoff was the Global Head of Translational Medicine Discovery and Profiling at Novartis, where he was an integral part of the successful development of five approved drugs and three that are currently in Phase III. Prior to Novartis, Dr. Roubenoff was Senior Director of Immunology and Research Development at Biogen, where he led the Translational Medicine and Early Development efforts of the Immunology Group. He has published extensively and devoted a significant portion of his career to research and education, teaching at Tufts University and Tufts Medical Center for 34 years. Prior to his career in the pharmaceutical industry, Dr. Roubenoff completed concurrent fellowships in Rheumatology and in Clinical Epidemiology at Johns Hopkins Hospital, where he was Chief Resident in Medicine. He received his MD from Northwestern University and his Master of Health Science from John Hopkins University.
Dave Guerin, Ph.D.
Senior Medicinal Chemistry Advisor
Dave is currently the Senior Medicinal Chemistry Advisor at Exo Therapeutics. To this role he brings more than 20 years of pharmaceutical industry experience. He was most recently the Head of Drug Discovery at RADD Pharmaceuticals (a seed-stage startup), responsible for leading a cross-functional team focused on drugging helicases towards the discovery of precision oncology therapeutics. Previously, Dave was a medicinal chemist and project leader at several large and small pharmaceutical companies where he developed hit identification, hit to lead and lead optimization expertise across various protein target classes (kinases, deubiquitinases, epigenetic enzymes, and others) for the treatment of cancer and inflammatory diseases. He is a co-inventor of TNG260, a novel small molecule inhibitor of the CoREST deacetylase complex for the treatment of STK11 mutated cancers, currently in Ph1/2 clinical trials. After graduating from the University of Rhode Island with a bachelor’s degree in pharmacy and a minor in chemistry, he earned his Ph.D. in synthetic organic chemistry from Boston College.
Kevin Leach, Ph.D., DABT
Senior Drug Development Advisor
Kevin Leach, Ph.D., DABT is a highly experienced non-clinical and translational scientist with over 20 years in the pharmaceutical industry. Prior to Exo, Dr. Leach held several leadership positions in non-clinical and translational research at biotechnology and pharmaceutical companies including a two-year stint as Vice President Non-Clinical and Translational Research of Spring Bank Research before it was acquired by F-Star Therapeutics. He has led teams in drug discovery and development across many therapeutic areas, including mental health, neurodegenerative disease, infectious disease and cancer including development of five approved drugs. Dr. Leach achieved his board certification in toxicology while at Shire Pharmaceuticals (Takeda), and he initiated an investigative toxicology effort during his five-year tenure at Merck. He received his BS in Biology from the University of Richmond and his Ph.D. in Biochemistry from Virginia Commonwealth University School of Medicine. He completed his Post Doctoral Fellowship in Biological Engineering at the Massachusetts Institute of Technology. He also serves as President of the Wellesley Cancer Prevention Project, a non profit focused on education for the prevention of cancer.
Alexandra Joseph
Senior Immunology Advisor
Dr. Joseph has over 20 years of experience in the biotech and pharmaceutical industry, having been responsible for building and overseeing multiple development platforms that have delivered candidates through translational, pre-clinical, and clinical studies. Prior to joining Exo, Dr. Joseph was Vice President of Research at ImmuneID, where she was responsible for building their industry-leading platform for precision therapeutics, resulting in multiple targets and biomarkers being developed for treatments in autoimmune disease. She also previously served as Head of Translational Research at Kiniksa Pharmaceuticals, where she was responsible for the design and implementation of translational research strategy for the company. Prior to that, during her 17-year tenure at Sanofi, Dr. Joseph held positions of increasing responsibility, culminating as Head of Scientific Portfolio Management and Operations, where she established and managed the Global Immunology and Inflammation Research Therapeutic Area and oversaw the discovery pipeline that delivered seven clinical candidates. Dr. Joseph received her PhD in Immunology from Tufts University Graduate School of Biomedical Science and completed her post-doctoral training at the Immune-Mediated Disease Institute at Harvard Medical School. She received a BA in Biology from Santa Clara University in California.
Dorothy Lou Bailey
President & CEO
Dorothy Lou Bailey is President & CEO at Exo Therapeutics. She brings over 10 years of experience in creating enduring value for biotech and pharmaceutical companies; including assisting in Exo’s recent Series B raise. Prior to joining Exo, Bailey worked as a corporate development and strategy consultant for VC firms and biotech companies. She also served in positions of increasing responsibility, ultimately as Head of Corporate Development at Blackthorn Therapeutics where she secured a $76 million financing and managed corporate strategy, licensing, search and evaluation. Before Blackthorn, she served as Principal at The Reckon Group, where she closed over $100 million in funding and co-development contracts as well as led new business development and capital strategy within the biopharmaceutical markets. Bailey earned her Bachelors with honors in Biology, Biochemistry & Molecular Genetics from Duke University.